atazanavir + dexamethasone

Atazanavir + dexamethasone is an oral combination drug regimen where **atazanavir** is a small molecule antiviral protease inhibitor and **dexamethasone** is a synthetic glucocorticoid corticosteroid. Atazanavir inhibits the HIV-1 and SARS-CoV-2 main protease, preventing viral replication by blocking proteolytic cleavage of viral polyproteins. Dexamethasone exerts potent anti-inflammatory and immunosuppressive effects by modulating gene expression via the glucocorticoid receptor, leading to decreased production of pro-inflammatory cytokines. The combination is currently studied for the treatment of COVID-19 infection to potentially offer both antiviral and anti-inflammatory benefits[3][1][4]. Atazanavir is primarily developed and manufactured for HIV infection; dexamethasone is a widely used corticosteroid for inflammatory and autoimmune conditions. Their combination in clinical trials is investigational and not approved for any disease. Atazanavir is metabolized via CYP3A4, and dexamethasone is also a CYP3A substrate, which creates potential for pharmacokinetic interactions, requiring dose management and monitoring[5].

Other names

atazanavir + dexamethasone